ILMN’s forward P/E was 20.75 respectively according to Yahoo Finance. Illumina stands as the dominant force in genetic sequencing, […] Insider Monkey • 3 days ago ILMN +0.67% ...

A panelist discusses the evolving role of prophylactic tocilizumab in reducing cytokine release syndrome during bispecific antibody therapy, enabling outpatient treatment and improving patient ...

The heterogeneity of isoform level m 6 A RNA methylation in single cells is unclear. The authors characterize m 6 A at both single-cell and isoform level through ONT long-read sequencing on single ...

The firm hopes that ETX-636's dual mechanism inhibiting mutant PI3Kα will give it an edge over competing products on the market.